Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by bfwon May 25, 2018 4:47pm
185 Views
Post# 28082712

RE:RE:RE:just sent an E-mail...

RE:RE:RE:just sent an E-mail...
PoorOpinion wrote:
bfw wrote:
FredTheVoice wrote:
Just sent an E-mail at TMX; could someone explain to me why they post a 4,96$ 52 year LOW, when the reality is more than 6$ ?

Good week for TH.

Good weekend to all.

FTV.


Hi Fred,

The stock traded under $5 in  November 2017 when the FDA delay news was released.

I remember it distinctly as I picked up some more shares that day.

bfw


Feeling good about that purchase I guess :)



Everybody should be feeling good about every purchase on TH at this point.

The stock is at an all time high (as far as I know). Every buyer should be in the green.

Truth be told, I feel lucky about the purchases first at 30 cents and then continuing under a dollar. However, I feel somewhat vindicated about the heavy purchases from $1.60 to $2 when the Ibalizumab deal was announced. I scratched my head numerous times on the announcement and lack of market reaction. I even contemplated going heavily in to leverage to buy even more shares at $2 (I should have!).

I, and others, are indebted to SPCEO (esp the worksheet but also ongoing sage advice) and jf for the  continued heavy due diligence (you should really start posting again!).

bfw

Bullboard Posts